Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study.

Song Chen,Feng Shi,Zhiqiang Wu,Liguang Wang,Hongjie Cai, Ping Ma,Yuanmin Zhou,Qicong Mai,Fan Wang,Shuangyan Tang,Wenquan Zhuang,Jiaming Lai,Xiaoming Chen,Huanwei Chen,Wenbo Guo

Journal of hepatocellular carcinoma（2023）

引用 3|浏览5

暂无评分

摘要

The combination of HAIC, lenvatinib, tislelizumab, and TAE was feasible in HCC patients with PVTT and high tumor burden, with tolerable safety.

查看译文

关键词

hepatic arterial infusion chemotherapy,portal vein tumor thrombus,hepatocellular carcinoma,unresectable hepatocellular carcinoma,arterial embolization

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要